(Total Views: 686)
Posted On: 08/05/2023 1:22:07 AM
Post# of 153886
Managers at CYDY regurlarly speak to the FDA. So...in addition to making careful judgements of which indication(s) to pursue, do you think it occured to management to also ASK the FDA and factor that into the equation. I got the idea listening to Tucker interview Devon Archer. Just like in Washington, a big part of getting FDA approval is lobbying/strategic advising/having great contact and access. Think "Scott Gotlieb" being on the board of Pfizer. Where is our Scott Gotlieb?
In the absence of great access, why not just ask the FDA which indication they deem more likely to get approved. Could this be a safe and effective approach? HIV? Could be, but ask.
In the absence of great access, why not just ask the FDA which indication they deem more likely to get approved. Could this be a safe and effective approach? HIV? Could be, but ask.
Quote:
Yes and I think I think they got to hear from HIV experts just how much potential LL has.
(3)
(0)
